文献速递药物相互作用特殊人群用药治疗药物监测与药物基因组学

利司扑兰机制性群体药动学建模估算FMO3个体发育及其对儿童药物相互作用的影响

Estimation of FMO3 Ontogeny by Mechanistic Population Pharmacokinetic Modelling of Risdiplam and Its Impact on Drug-Drug Interactions in Children.
PubMed 文献 · Clin Pharmacokinet · 2023-05-06

该研究利用利司扑兰的机制性群体药动学模型,基于525名2月龄至61岁受试者的10205个血药浓度数据,估算体内FMO3个体发育。六种模型一致预测儿童FMO3表达/活性高于成人,2岁时达最大,约为成人的三倍。该个体发育函数改善儿童利司扑兰药动学预测,对双CYP3A-FMO3底物的模拟显示儿童CYP3A受害药DDI倾向与成人相当或降低。

要点

  • 儿童FMO3表达/活性高于成人,2岁时达峰值,约为成人三倍。
  • 体内FMO3个体发育函数较体外函数更好预测儿童利司扑兰药动学。
  • 利司扑兰在儿童中CYP3A受害药或肇事药的DDI风险仍为低。

核心结论

  • 机制性群体药动学建模成功从利司扑兰数据估算体内FMO3个体发育。
  • 儿童FMO3表达/活性高于成人,2岁时达最大,约为成人三倍。
  • 该体内FMO3个体发育函数有助于预测其他FMO3底物在儿童中的药动学和DDI。

研究设计与样本

  • 研究整合利司扑兰开发期间的群体和生理药动学模型,构建机制性群体药动学模型。
  • 纳入525名2月龄至61岁受试者的10205个利司扑兰血浆浓度-时间数据。
  • 考察六种结构模型描述体内FMO3个体发育。

主要发现

  • 六种模型一致预测儿童FMO3表达/活性高于成人,2岁时达最大,约为成人三倍。
  • 小于4月龄婴儿的FMO3个体发育轨迹六种模型预测不同,可能因该年龄段观察有限。
  • 体内FMO3个体发育函数较体外函数改善儿童利司扑兰药动学预测。
  • 双CYP3A-FMO3理论底物模拟显示儿童CYP3A受害药DDI倾向与成人相当或降低。
  • 利司扑兰模型细化FMO3个体发育对已预测的低CYP3A受害药或肇事药DDI风险无影响。

关键数值与推荐

  • 利司扑兰主要经FMO3和CYP3A代谢,分别占75%和20%。
  • 模拟的理论底物代谢分数为fmCYP3A:fmFMO3=10%:90%、50%:50%、90%:10%。

临床怎么用

  • 临床可参考儿童FMO3个体发育规律评估FMO3底物或双CYP3A-FMO3底物的药动学和DDI。
  • 利司扑兰在儿童中CYP3A相关DDI风险低,模型细化未改变该结论。

局限性

  • 小于4月龄婴儿观察数据有限,FMO3个体发育轨迹预测存在不确定性。
  • 研究基于利司扑兰数据间接估算FMO3个体发育,非直接测定FMO3活性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: Spinal muscular atrophy (SMA) is a progressive neuromuscular disease caused by insufficient levels of survival motor neuron (SMN) protein. Risdiplam (EvrysdiTM) increases SMN protein and is approved for the treatment of SMA. Risdiplam has high oral bioavailability and is primarily eliminated through hepatic metabolism by flavin-containing monooxygenase3 (FMO3) and cytochrome P450 (CYP) 3A, by 75% and 20%, respectively. While the FMO3 ontogeny is critical input data for the prediction of risdiplam pharmacokinetics (PK) in children, it was mostly studied in vitro, and robust in vivo FMO3 ontogeny is currently lacking. We derived in vivo FMO3 ontogeny by mechanistic population PK modelling of risdiplam and investigated its impact on drug-drug interactions in children. METHODS: Population and physiologically based PK (PPK and PBPK) modelling conducted during the development of risdiplam were integrated into a mechanistic PPK (Mech-PPK) model to estimate in vivo FMO3 ontogeny. A total of 10,205 risdiplam plasma concentration-time data from 525 subjects aged 2 months-61 years were included. Six different structural models were examined to describe the in vivo FMO3 ontogeny. Impact of the newly estimated FMO3 ontogeny on predictions of drug-drug interaction (DDI) in children was investigated by simulations for dual CYP3A-FMO3 substrates including risdiplam and theoretical substrates covering a range of metabolic fractions (fm) of CYP3A and FMO3 (fmCYP3A:fmFMO3 = 10%:90%, 50%:50%, 90%:10%). RESULTS: All six models consistently predicted higher FMO3 expression/activity in children, reaching a maximum at the age of 2 years with an approximately threefold difference compared with adults. Different trajectories of FMO3 ontogeny in infants < 4 months of age were predicted by the six models, likely due to limited observations for this age range. Use of this in vivo FMO3 ontogeny function improved prediction of risdiplam PK in children compared to in vitro FMO3 ontogeny functions. The simulations of theoretical dual CYP3A-FMO3 substrates predicted comparable or decreased CYP3A-victim DDI propensity in children compared to adults across the range of fm values. Refinement of FMO3 ontogeny in the risdiplam model had no impact on the previously predicted low CYP3A-victim or -perpetrator DDI risk of risdiplam in children. CONCLUSION: Mech-PPK modelling successfully estimated in vivo FMO3 ontogeny from risdiplam data collected from 525 subjects aged 2 months-61 years. To our knowledge, this is the first investigation of in vivo FMO3 ontogeny by population approach using comprehensive data covering a wide age range. Derivation of a robust in vivo FMO3 ontogeny function has significant implications on the prospective prediction of PK and DDI in children for other FMO3 substrates in the future, as illustrated in the current study for FMO3 and/or dual CYP3A-FMO3 substrates. CLINICAL TRIAL REGISTRY NUMBERS: NCT02633709, NCT03032172, NCT02908685, NCT02913482, NCT03988907.

来源:Clin Pharmacokinet,查看原文。版权归原作者所有。

引用

  1. Cleary Y, Kletzl H, Grimsey P, et al. Estimation of FMO3 Ontogeny by Mechanistic Population Pharmacokinetic Modelling of Risdiplam and Its Impact on Drug-Drug Interactions in Children. Clin Pharmacokinet. 2023. PMID: 37148485. doi:10.1007/s40262-023-01241-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。